KR102012164B1 - 점막염치료를 위한 조성물 - Google Patents

점막염치료를 위한 조성물 Download PDF

Info

Publication number
KR102012164B1
KR102012164B1 KR1020137033195A KR20137033195A KR102012164B1 KR 102012164 B1 KR102012164 B1 KR 102012164B1 KR 1020137033195 A KR1020137033195 A KR 1020137033195A KR 20137033195 A KR20137033195 A KR 20137033195A KR 102012164 B1 KR102012164 B1 KR 102012164B1
Authority
KR
South Korea
Prior art keywords
independently
alkyl
group
halo
npl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137033195A
Other languages
English (en)
Korean (ko)
Other versions
KR20140078582A (ko
Inventor
리차드 더블유 스코트
보제나 콜크작
Original Assignee
이노베이션 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노베이션 파마슈티컬스 인코포레이티드 filed Critical 이노베이션 파마슈티컬스 인코포레이티드
Publication of KR20140078582A publication Critical patent/KR20140078582A/ko
Application granted granted Critical
Publication of KR102012164B1 publication Critical patent/KR102012164B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020137033195A 2011-05-16 2012-05-15 점막염치료를 위한 조성물 Expired - Fee Related KR102012164B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486455P 2011-05-16 2011-05-16
US61/486,455 2011-05-16
PCT/US2012/037895 WO2012158672A2 (en) 2011-05-16 2012-05-15 Compounds for use in treatment of mucositis

Publications (2)

Publication Number Publication Date
KR20140078582A KR20140078582A (ko) 2014-06-25
KR102012164B1 true KR102012164B1 (ko) 2019-08-20

Family

ID=47175383

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033195A Expired - Fee Related KR102012164B1 (ko) 2011-05-16 2012-05-15 점막염치료를 위한 조성물

Country Status (14)

Country Link
US (6) US8802683B2 (enExample)
EP (1) EP2709619B1 (enExample)
JP (1) JP5833745B2 (enExample)
KR (1) KR102012164B1 (enExample)
CN (1) CN103957710B (enExample)
AU (1) AU2012255935B2 (enExample)
CA (1) CA2836099C (enExample)
DK (1) DK2709619T3 (enExample)
IL (1) IL229381B (enExample)
MX (1) MX2013013330A (enExample)
RU (1) RU2606128C2 (enExample)
TW (1) TWI520951B (enExample)
WO (1) WO2012158672A2 (enExample)
ZA (1) ZA201308541B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
RU2606128C2 (ru) 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
CN104981249B (zh) * 2012-12-18 2018-06-19 英国卫生部 抗微生物化合物、它们的合成及其应用
JP6474736B2 (ja) * 2013-02-15 2019-02-27 テヒーニィシエ ウニヴェルジテート ベルリン アルビシジン誘導体、その使用および合成
BR112015022224A2 (pt) 2013-03-15 2017-07-18 Genzyme Corp poliamidas de amina funcional
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
JP2024532086A (ja) 2021-08-30 2024-09-05 ユニケム ラボラトリーズ リミテッド 炎症性疾患の処置のためのタンパク質組成物
CN114890982A (zh) * 2022-05-16 2022-08-12 内蒙古大学 一种季铵盐修饰的二苯并噻吩亚砜衍生物的制备方法
CN117402075B (zh) * 2023-10-17 2026-01-09 厦门大学深圳研究院 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080939A2 (en) * 2001-01-18 2002-10-17 Genzyme Corporation Ionene polymers and their use as antimicrobial agents
US20100105703A1 (en) * 2008-10-27 2010-04-29 Polymedix, Inc. Synthetic Mimetics Of Host Defense And Uses Thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
US5656591A (en) 1992-01-23 1997-08-12 Morinaga Milk Industry Co., Ltd. Antimicrobial agents and method for treating products therewith
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
CA2340912C (en) 1998-08-20 2008-11-18 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6440964B1 (en) 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
DE60135572D1 (de) 2000-11-08 2008-10-09 Fxs Ventures Llc Verbesserte ophthalmologische und kontaktlinsenlösungen mit einer peroxidquelle und einem kationischen polymeren konservierungsmittel
EP2289524A1 (en) 2001-03-08 2011-03-02 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers as anti-infective agents
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
AR034372A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AU2002341566A1 (en) * 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
JP2005529158A (ja) 2002-05-28 2005-09-29 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 両親媒性ポリマーのコンピュータ分析および設計のための方法、システムおよびコンピュータプログラム製品
AU2003239212A1 (en) 2002-06-13 2003-12-31 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembranes using coarse grain models
WO2004046109A2 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Ionene oligomers and polymers
CA2519023C (en) * 2003-03-17 2014-05-20 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2004082643A2 (fr) 2003-03-20 2004-09-30 Shiseido International France Composition cosmetique
US20040202687A1 (en) 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
TWI388280B (zh) 2004-01-23 2013-03-11 Univ Pennsylvania 面上兩性之聚芳基和聚芳炔基聚合物與寡聚物及其用途
EP2380872B1 (en) 2004-06-15 2014-04-23 Cellceutix Corporation Polycationic compounds and uses thereof
WO2006132647A2 (en) 2004-07-23 2006-12-14 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
EP2301349A2 (en) 2005-02-25 2011-03-30 The Trustees of The University of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
EP1704860B1 (en) * 2005-03-24 2010-10-27 Rottapharm S.P.A. Benzamidine derivatives for treatment and prevention of mucositis
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
MX2011000971A (es) 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
RU2011128373A (ru) * 2008-12-10 2013-01-20 Полимедикс, Инк. Молекулы с антимикробной активностью в отношении штаммов микобактерий с множественной лекарственной устойчивостью и широкой лекарственной устойчивостью
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
WO2011084970A1 (en) * 2010-01-07 2011-07-14 Polymedix Inc. Anti-heparin compounds
TW201208677A (en) * 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
RU2606128C2 (ru) * 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
AU2012352621A1 (en) * 2011-12-13 2014-07-24 Cellceutix Corporation Cyclic compounds and methods of making and using the same
BR112014017642A2 (pt) * 2012-01-18 2019-09-24 Cellceutix Corp método para exterminar ou inibir o desenvolvimento de uma espécie de candida ou aspergillus ou prevenir ou tratar o mamífero apresentando candidíase oral ou disseminada ou uma infecção por aspergillus, composto, e, uso de um composto
US20140171438A1 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid Compounds And Methods Of Making And Using The Same
US20140308317A1 (en) * 2012-12-10 2014-10-16 Cellceutix Corporation Polymeric Compounds And Methods Of Making And Using The Same
CN105246476B (zh) * 2013-05-28 2019-11-15 莫弗凯姆联合化学股份公司 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080939A2 (en) * 2001-01-18 2002-10-17 Genzyme Corporation Ionene polymers and their use as antimicrobial agents
US20100105703A1 (en) * 2008-10-27 2010-04-29 Polymedix, Inc. Synthetic Mimetics Of Host Defense And Uses Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N Engl J Med*

Also Published As

Publication number Publication date
TW201247654A (en) 2012-12-01
US20190282521A1 (en) 2019-09-19
DK2709619T3 (en) 2018-01-15
US10603294B2 (en) 2020-03-31
JP2014516033A (ja) 2014-07-07
RU2013155678A (ru) 2015-06-27
IL229381A0 (en) 2014-01-30
WO2012158672A2 (en) 2012-11-22
EP2709619B1 (en) 2017-10-11
US20160213668A1 (en) 2016-07-28
US20120295922A1 (en) 2012-11-22
EP2709619A2 (en) 2014-03-26
US20170224640A1 (en) 2017-08-10
TWI520951B (zh) 2016-02-11
CN103957710B (zh) 2016-04-20
KR20140078582A (ko) 2014-06-25
CA2836099A1 (en) 2012-11-22
CN103957710A (zh) 2014-07-30
US10206894B2 (en) 2019-02-19
MX2013013330A (es) 2014-07-09
RU2606128C2 (ru) 2017-01-10
WO2012158672A3 (en) 2014-05-08
CA2836099C (en) 2020-06-16
IL229381B (en) 2018-04-30
US9795575B2 (en) 2017-10-24
AU2012255935B2 (en) 2016-06-23
US20140364364A1 (en) 2014-12-11
JP5833745B2 (ja) 2015-12-16
NZ618249A (en) 2016-03-31
ZA201308541B (en) 2015-04-29
US8802683B2 (en) 2014-08-12
US20180064664A1 (en) 2018-03-08
US9457027B2 (en) 2016-10-04
EP2709619A4 (en) 2015-04-22
US9155738B2 (en) 2015-10-13

Similar Documents

Publication Publication Date Title
US10603294B2 (en) Compounds for use in treatment of mucositis
AU2012255935A1 (en) Compounds for use in treatment of mucositis
US20110178104A1 (en) Anti-Heparin Compounds
JPS63192758A (ja) １‐（４‐ヒドロキシ‐３，５‐ジ‐ｔｅｒｔ．‐ブチルベンゾイル）ホモピペラジンおよびその誘導体
JP2008531585A (ja) 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
US4603133A (en) Amides and esters of 2-[N-(morpholinoalkyl)aminosulfonyl]-6-nitrobenzoic acids and compositions useful as adjuncts to radiation therapy
WO1989005637A1 (en) Improving toxicity profiles in chemotherapy
JP2013530244A (ja) 免疫調節の方法
US4647588A (en) 2-(substituted sulfamyl)-6-nitrobenzoic acid amides and pharmaceutical compositions
NZ618249B2 (en) Compounds for use in treatment of mucositis
US4853415A (en) 2-(substituted sulfamyl) derivatives of 4-nitrobenzamide as radiation sensitizers
EP0270292A2 (en) Radiation sensitizers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220728

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240814

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240814